(Head and Neck Cancer) Effectiveness of Palbociclib + Cetuximab?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
This phase II clinical trial by multiple institutions evaluated the combination of Palbociclib (Ibrance) + Cetuximab (Erbitux) in patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma. The primary endpoint was the objective response rate. The study assessed whether this combination could provide clinical benefit in patients who had progressed after prior platinum-based therapy.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5